If you are a patient interested in participating in our ongoing clinical studies, please contact the relevant hospital department listed below directly to inquire about enrollment.
Ongoing Clinical Trials
Confirmatory Clinical Study of REGEND001 in COPD (A Multicenter, Randomized, Blinded, Placebo-Controlled Trial)
This study is designed to evaluate the efficacy and safety of REGEND001, an autologous cell therapy, in patients with chronic obstructive pulmonary disease (COPD).
-
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University
Address:
No. 28 Qiaozhong Middle Road, Liwan District, Guangzhou (Datansha Campus) / No.151 Yanjiang West Road, Yuexiu District, Guangzhou (Yanjiang Campus)
Eligibility – Who Can Join?
Key Inclusion Criteria (must meet all)
- Aged 40 to 75 years (inclusive) at the time of informed consent
- Diagnosed with COPD in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 guidelines
- Evidence of emphysema on high-resolution CT (HRCT)
- Hemoglobin-corrected DLCO (% predicted) ≥20% and <80%
- COPD Assessment Test (CAT) score ≥3
Key Exclusion Criteria (any one excludes)
- At screening, participants with a positive result for any of the following tests—Treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody—are excluded except in the following cases:
-
Hepatitis B virus carriers (HBsAg‑positive only, without signs or symptoms of hepatitis, with normal liver function tests or clinically insignificant abnormalities as assessed by the investigator, and a viral load <1000 copies/mL or 200 IU/mL);
-
Patients with cured hepatitis C (negative HCV ribonucleic acid [RNA] test);
-
Persistent negative result on the toluidine red unheated serum test (TRUST) for non‑treponemal antibodies.
-
-
Participants diagnosed with pneumonia (including bacterial, fungal, or viral pneumonia, excluding cases identified on imaging that required no treatment or management) within 3 months prior to screening are excluded.
Clinical Study of REGEND003 Autologous Cell Infusion for Type 2 Diabetes with Chronic Kidney Disease (CKD)
Phase I clinical study evaluating the safety and feasibility of autologous renal progenitor cell infusion
-
Renal Medicine Department, Tongji Hospital of Tongji University
Address:
No. 389, Xincun Road, Putuo District, Shanghai, China
Eligibility – Who Can Join?
Key Inclusion Criteria (must meet all)
- 30–75 years of age at the time of signing the informed consent form;
- Diagnosed with Type 2 Diabetes Mellitus for at least 1 year;
- Diagnosed with Chronic Kidney Disease (CKD);
- Willing and able to provide informed consent and comply with all study procedures and assessments.
Key Exclusion Criteria (any one excludes)
- Pregnancy, breastfeeding, or plans to become pregnant within one year after cell infusion (for female participants or their male partners);
- Positive screening results for syphilis (TP-Ab), HIV, hepatitis B-surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), except for:
- Inactive HBV carriers (HBsAg‑positive only, without signs or symptoms of hepatitis, with normal liver function tests or clinically insignificant abnormalities as assessed by the investigator)
- Cured HCV patients (HCV RNA negative).
- Patients with Type 1 Diabetes Mellitus;
- Patients undergoing regular hemodialysis or peritoneal dialysis;
